Adipose PD-L1 Modulates PD-1/PD-L1 Checkpoint Blockade Immunotherapy Efficacy in Breast Cancer

Programmed death-ligand 1 (PD-L1) and its receptor programmed cell death protein 1 (PD-1) modulate antitumor immunity and are major targets of checkpoint blockade immunotherapy. However, clinical trials of anti-PD-L1 and anti-PD-1 antibodies in breast cancer demonstrate only modest efficacy. Further...

Descripción completa

Detalles Bibliográficos
Autores principales: Wu, Bogang, Sun, Xiujie, Gupta, Harshita B., Yuan, Bin, Li, Jingwei, Ge, Fei, Chiang, Huai-Chin, Zhang, Xiaowen, Zhang, Chi, Zhang, Deyi, Yang, Jing, Hu, Yanfen, Curiel, Tyler J., Li, Rong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2018
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6209395/
https://www.ncbi.nlm.nih.gov/pubmed/30393583
http://dx.doi.org/10.1080/2162402X.2018.1500107

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6209395/
https://www.ncbi.nlm.nih.gov/pubmed/30393583
http://dx.doi.org/10.1080/2162402X.2018.1500107

Ejemplares similares